Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea

BACKGROUND: Delamanid, bedaquiline, and linezolid have recently been approved for the treatment of multidrug- and extensively drug-resistant (MDR and XDR, respectively) tuberculosis (TB). To use these drugs effectively, drug susceptibility tests, including rapid molecular techniques, are required fo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Lab Med
Main Authors: Yang, Jeong Seong, Kim, Kyung Jong, Choi, Hongjo, Lee, Seung Heon
Formato: Artigo
Idioma:Inglês
Publicado em: The Korean Society for Laboratory Medicine 2018
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6056398/
https://ncbi.nlm.nih.gov/pubmed/30027700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3343/alm.2018.38.6.563
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados